PTPRO — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL21968899	0.81	2/20
SCHEMBL16706086	0.73	2/20
SCHEMBL8358339	0.54	2/20
SCHEMBL21966580	0.49	2/20
SCHEMBL12443639	0.45	2/20
SCHEMBL1733827	1.00	1/20
SCHEMBL31358805	1.00	1/20
Hydrochloric Acid (SCHEMBL1815540)	0.98	1/20
SCHEMBL1734805	0.92	1/20
SCHEMBL1734802	0.89	1/20
SCHEMBL1289398	0.86	1/20
SCHEMBL1981176	0.86	1/20
SCHEMBL1982094	0.86	1/20
SCHEMBL1982416	0.86	1/20
SCHEMBL1982586	0.86	1/20
SCHEMBL1983494	0.86	1/20
SCHEMBL1984856	0.86	1/20
SCHEMBL1986204	0.86	1/20
Zinc Ion (SCHEMBL1986679)	0.86	1/20
SCHEMBL11133730	0.86	1/20

Clinical trials — most relevant to PTPRO by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Pegylated-Interferon and Ribavirin Plus Metformin in the Treatment of Chronic HCV Infection and Insulin Resistance	PHASE4	UNKNOWN
Regulatory Lymphocytes in Patients Treated With Specific Immunotherapy	PHASE4	COMPLETED
SGLT2i Safety and Efficacy on Kidney Allograft Function in Non-diabetic Kidney Transplant Recipients	PHASE4	RECRUITING
A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia	PHASE3	RECRUITING
Use of Selective JAK Inhibitor in ILD and Skin Tightness of Systemic Sclerosis Versus MMF	PHASE3	COMPLETED
Pembrolizumab Plus Enfortumab Vedotin in Collecting Duct and Renal Medullary Carcinoma	PHASE2	RECRUITING
Pembrolizumab And Tamoxifen Among Women With Advanced Hormone Receptor Positive Breast Cancer And Esr1 Mutation	PHASE2	UNKNOWN
Pembrolizumab and Induction Chemotherapy in Head and Neck Squamous Cell Carcinoma (PICH Study)	PHASE1/PHASE2	WITHDRAWN
Pembrolizumab (MK-3475) in MM Patients With Residual Disease	PHASE2	COMPLETED
Study in Adult Ph-positive ALL	PHASE2	UNKNOWN
Temsirolimus With or Without Megestrol Acetate and Tamoxifen Citrate in Treating Patients With Advanced, Persistent, or Recurrent Endometrial Cancer	PHASE2	COMPLETED
Imatinib in Dermatofibrosarcoma Protuberans (DFSP)	PHASE1/PHASE2	COMPLETED
Lapatinib Ditosylate in Treating Patients With Unresectable Liver or Biliary Tract Cancer	PHASE2	COMPLETED
Cyclosporine For The Treatment Of COVID-19(+)	PHASE2	COMPLETED
Phase I Study of SC-43 Oral Solution in Subjects With Refractory Solid Tumors	PHASE1	WITHDRAWN
Bioequivalence Study of Tacrolimus in Healthy Volunteers	PHASE1	COMPLETED
A Study of JNJ-75348780 in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)	PHASE1	COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma	PHASE1	COMPLETED
Lymphoid Tyrosine Phosphatase Gene Polymorphisms in Inflammatory Bowel Disease	nan	UNKNOWN
Monitoring of Breathing Effort Through Pressure Time Product Measurement Using Airway Occlusion Pressure	nan	UNKNOWN
Evaluation of the Level of Expression of CD45RC on T Lymphocytes as a Predictive Biomarker of Acute Rejection After Renal Transplantation	nan	RECRUITING
C-X-C Chemokine Receptor 4 in Chronic Lymphocytic Leukemia	nan	UNKNOWN
Role of NFKBIA and PTPN22 Genes Polymorphism in Acute Rejection Susceptibility After Living Donor Liver Transplantation in Egyptian Patients.	nan	COMPLETED
Expression of CD19 Complex in Lymphoproliferative Disorders	nan	UNKNOWN
Avapritinib in the Treatment of Unresectable or Recurrent Metastatic GIST Non-exon18 Mutations of PDGFRA	nan	RECRUITING
The Effect of 0.1% Topical Ciclosporin A for 12-weeks on the Eye Surface Immune Cells in Dry Eyes	nan	RECRUITING
Cardiovascular Effects of Empagliflozine	nan	UNKNOWN
Modulatory Effect of Prodigiosin or Pioglitazone on TIME and the Crosstalk to Immune-Checkpoint Protein(s)	nan	NOT_YET_RECRUITING
Longitudinal Prognosis of Lymphoproliferative Manifestations in Primary Immunodeficiencies	nan	NOT_YET_RECRUITING
The Effect Of DAAs on miRNA-122 And Insulin Resistance In Chronic HCV Patients	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a PTPRO binder may also engage these)

Protein	Name	Similarity
E9Q612	—	0.997	E9Q612 →
P52583	—	0.990	P52583 →
P04157	—	0.989	P04157 →
Q9MYL0	—	0.989	Q9MYL0 →
P16620	—	0.989	P16620 →
Q96PD2	—	0.989	Q96PD2 →
Q5GIT4	—	0.989	Q5GIT4 →
Q9H7T0	—	0.989	Q9H7T0 →
P0DP43	—	0.989	P0DP43 →
Q62959	—	0.988	Q62959 →
P22650	—	0.988	P22650 →
P48356	—	0.988	P48356 →
Q9QJ17	—	0.988	Q9QJ17 →
PTPRJ	Receptor-type tyrosine-protein phosphatase eta	0.988	landscape →
P18535	—	0.987	P18535 →
Q8I7I5	—	0.987	Q8I7I5 →
P09258	—	0.987	P09258 →
O18016	—	0.987	O18016 →
P33500	—	0.987	P33500 →
Q8AXC7	—	0.987	Q8AXC7 →
PTPRM	Receptor-type tyrosine-protein phosphatase mu	0.987	landscape →
P22651	—	0.987	P22651 →
Q77NN4	—	0.987	Q77NN4 →
Q29000	—	0.987	Q29000 →
Q9WVT0	—	0.987	Q9WVT0 →
P26619	—	0.986	P26619 →
Q28889	—	0.986	Q28889 →
Q9JM61	—	0.986	Q9JM61 →
Q8IZF2	—	0.986	Q8IZF2 →
O02671	—	0.986	O02671 →